TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BerGenBio ASA ( (BRRGF) ) has issued an update.
Oncoinvent ASA has successfully completed a fully underwritten rights issue, raising NOK 130 million through the allocation of 260 million new shares. This capital increase, subject to regulatory approvals, will enhance Oncoinvent’s financial position, supporting its ongoing clinical trials and strengthening its market presence in the biotechnology sector.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
Oncoinvent is a clinical-stage biotechnology company focused on developing novel radiopharmaceutical therapies for cancer treatment. Their lead product, Radspherin®, targets micro-metastases in the peritoneum post-surgery, utilizing radium-224 for direct targeting with minimal harm to healthy tissue. The company is actively engaged in clinical trials and operates a manufacturing facility in Oslo.
Average Trading Volume: 443,119
Current Market Cap: NOK208.3M
Learn more about BRRGF stock on TipRanks’ Stock Analysis page.